ENTRY INTO DEED OF ASSIGNMENT IN RELATION TO THE SALE & PURCHASE AGREEMENT & DEED OF SHARE CHARGE

Rights: Voluntary

[Withdrawal] Rights: Voluntary

AMENDMENT TO TERMS OF SALE AND PURCHASE AGREEMENT, DEED OF SHARE CHARGE AND DEED OF AMENDMENT

[Replacement] Rights: Voluntary

Rights: Voluntary

Financial Statements and Related Announcement: Half Yearly Results

REALLOCATION AND UPDATE ON THE UTILISATION OF THE PROCEEDS FROM THE IPO AND PLACEMENT OF SHARES

Change of Share Registrar and Place where the Register of Members and Index is Kept

Change of Company Secretary

AMENDMENT TO TERMS OF SALE AND PURCHASE AGREEMENT, DEED OF SHARE CHARGE AND DEED OF AMENDMENT

Change of Company Secretary

Resignation of Chief Scientific Officer

Change - Announcement of Appointment: Appointment of Financial Controller

Annual General Meeting: Voluntary

Resignation of Financial Controller

[Replacement] Annual General Meeting: Voluntary

Announcement in Relation to Regulatory Actions by SGX and/or Other Authorities: RESPONSE TO QUERIES BY SGX REGCO ON THE COMPANY'S FY2021 ANNUAL REPORT

Annual Reports & Related Documents: Annual Report

Annual General Meeting: Voluntary

Financial Statements and Related Announcement: Auditor's Comments of Accounts

Resignation of Executive Officer - Director of Corporate Finance and Corporate Development

Financial Statements and Related Announcement: Full Yearly Results

Financial Statements and Related Announcement: Profit Guidance

Announcement in Relation to Regulatory Actions by SGX and/or Other Authorities: RESPONSE TO QUERIES BY SGX REGCO ON THE COMPANY'S ANNOUNCEMENTS OF 7 FEBRUARY 2022

CHANGES TO THE COMPOSITION OF THE BOARD OF DIRECTORS AND BOARD COMMITTEES OF THE COMPANY

Change - Announcement of Appointment: Re-designation of Independent Director to Non-Executive Independent Chairman

Resignation of Non-Executive Non-Independent Chairman

Disclosure of Director's Interest - Song Tang Yih

APPROVAL BY SINGAPORE'S MOH FOR MEDICAL MICROBIOLOGY (MOLECULAR MICROBIOLOGY) SERVICES

AMENDMENT TO TERMS OF SALE AND PURCHASE AGREEMENT AND DEED OF SHARE CHARGE DATED 27 MARCH 2020

FURTHER UPDATE ON DEVELOPMENT OF THE CLEAREPI SARS-COV-2 NEUTRALISING ANTIBODY RAPID TEST KIT

Change - Announcement of Appointment: Appointment of Independent Director

RESIGNATION AND APPOINTMENT OF AN ID; CHANGES TO THE COMPOSITION OF THE BOARD AND BOARD COMMITTEES

Resignation of Independent Director

UPDATE ON DEVELOPMENT OF THE CLEAREPI SARS-COV-2 NEUTRALISING ANTIBODY RAPID TEST KIT

Response to SGX Queries: On Other Announcements

Change - Announcement of Appointment: Appointment of Director of Corporate Finance and Corporate Development

Change - Announcement of Appointment: Re-designation of Interim Chief Executive Officer as Chief Scientific Officer

Change - Announcement of Appointment: Appointment of Executive Director and Chief Executive Officer

Appointment and Re-designation of directors; and Changes to the composition of the Board

Financial Statements and Related Announcement: Half Yearly Results

UPDATE ON ISSUANCE OF NOTICE OF ARBITRATION TO SYSMEX: ENTERING INTO OF SETTLEMENT AGREEMENT

Resignation of Chief Operating Officer - Ms Wang Qingyin

CHANGES TO THE COMPOSITION OF THE BOARD COMMITTEES OF THE COMPANY

Change - Announcement of Appointment: Appointment as Independent Director

APPOINTMENT OF INDEPENDENT DIRECTOR AND CHANGES TO THE COMPOSITION OF THE BOARD

Minutes of Extraordinary General Meeting held on 30 April 2021

Minutes of Annual General Meeting held on 30 April 2021

CHANGES TO THE COMPOSITION OF THE BOARD COMMITTEES OF THE COMPANY

Change in Director's Interest - Yee Pinh Jeremy

ALLOTMENT AND ISSUANCE OF NEW ORDINARY SHARES

[Replacement] Extraordinary/ Special General Meeting: Voluntary

[Replacement] Annual General Meeting: Voluntary

Extraordinary/ Special General Meeting: Voluntary

Annual Reports & Related Documents: Annual Report

Annual General Meeting: Voluntary

RETIREMENT AND APPOINTMENT OF INDEPENDENT DIRECTORS; AND CHANGES TO THE COMPOSITION OF THE BOARD

Retirement of Independent Director - Toh Shih Hua

Change - Announcement of Appointment: Appointment of Independent Director - Kong Chee Keong

Retirement of Independent Director - Mr Ong Hsien Chih, James (Weng Xianzhi, James)

Change - Announcement of Appointment: Appointment of Independent Director - Chia Beng Kwan

CLEAREPI ANTIGEN RAPID TEST KIT - PRODUCT AUTHORISATION IN INDONESIA

Financial Statements and Related Announcement: Full Yearly Results

LAUNCH OF CLEAREPI ART AND RECEIPT OF CONFIRMATION FOR CE MARKING

Annual Reports & Related Documents: Sustainability Report

RESIGNATION OF AN INDEPENDENT DIRECTOR AND CHANGES TO THE COMPOSITION OF THE BOARD AND RC

Resignation of Independent Director

DISTRIBUTION AGREEMENT WITH JOYSBIO & EXPANSION OF ONGOING SALE AND DISTRIBUTION OF PRODUCTS

COVID-19 ANTIBODY TEST KITS: RECEIPT OF PRODUCT AUTHORISATION IN INDONESIA

CORRECTION IN ANNOUNCEMENT RELATING TO THE UPDATE ON ISSUANCE OF LOD TO SYSMEX

UPDATE ON ISSUANCE OF LETTER OF DEMAND TO SYSMEX CORPORATION

ISSUANCE OF LETTER OF DEMAND TO SYSMEX CORPORATION

PROPOSED ISSUANCE OF UP TO 2,723,500 SHARES - ALLOTMENT AND ISSUANCE OF 1,168,000 SHARES

PROPOSED ISSUANCE OF UP TO 2,723,500 SHARES - RECEIPT OF LISTING AND QUOTATION NOTICE

Response to SGX Queries: On Other Announcements

DISCLOSURE IN CHANGE OF INTEREST OF SUBSTANTIAL SHAREHOLDER(S) - CLEARBRIDGE BSA PTE. LTD.

CHANGES IN DIRECTOR'S INTEREST - YEE PINH JEREMY

ALLOTMENT AND ISSUANCE OF NEW SHARES PURSUANT TO THE VESTING OF SHARE AWARDS UNDER THE PSP

CHANGES IN DIRECTOR'S INTEREST - YEE PINH JEREMY

PROPOSED ISSUANCE OF UP TO 2,723,500 NEW ORDINARY SHARES IN BIOLIDICS

GRANT OF SHARE AWARDS PURSUANT TO THE BIOLIDICS PERFORMANCE SHARE PLAN

ANNOUNCEMENT PURSUANT TO RULE 706A OF THE LISTING MANUAL

Financial Statements and Related Announcement: Half Yearly Results

Response to SGX Queries: On Other Announcements

Regulatory Actions By SGX: Queries by SGX RegCo on the Company's announcement of 14 July 2020

Request for Lifting of Trading Halt - Sponsor's Statement

Request for Lifting of Trading Halt: REQUEST FOR LIFTING OF TRADING HALT

LICENCE AGREEMENT WITH ACCELERATE TECHNOLOGIES PTE LTD

Request for Trading Halt: REQUEST FOR TRADING HALT

Response to SGX Queries: On Other Announcements

COLLABORATION WITH LC-BIO TECHNOLOGIES (HANGZHOU) CO., LTD.

Response to SGX Queries: On Other Announcements

COVID-19 ANTIBODY TEST KITS: FURTHER US MARKET UPDATE

COVID-19 ANTIBODY TEST KITS: US MARKET UPDATE

PROPOSED ACQUISITION OF THE ENTIRE SHARE CAPITAL OF BIOMEDICS LABORATORY PTE. LTD. - COMPLETION

Minutes of Extraordinary General Meeting held on 30 April 2020

Minutes of Annual General Meeting held on 30 April 2020

APPOINTMENT OF CLEARBRIDGE MEDICAL GROUP PTE LTD AS NON-EXCLUSIVE DISTRIBUTOR

MEDIPROUD APPOINTED AS NON-EXCLUSIVE DISTRIBUTOR OF BIOLIDICS' COVID-19 TEST KITS IN THAILAND

[Replacement] Extraordinary/ Special General Meeting: Voluntary

[Replacement] Annual General Meeting: Voluntary

RESPONSE TO QUESTIONS RECEIVED FROM SHAREHOLDERS AND SIAS PRIOR TO THE COMPANY'S AGM AND EGM

Response to SGX Queries: On Other Announcements

Request for Lifting of Trading Halt - Sponsor's Statement

Request for Lifting of Trading Halt: Request for Lifting of Trading Halt

APPOINTMENT OF AYTU BIOSCIENCE AS EXCLUSIVE DISTRIBUTOR FOR BIOLIDICS' COVID-19 RAPID TEST KITS

Response to SGX Queries: On Other Announcements

Request for Trading Halt: REQUEST FOR TRADING HALT

Query Regarding Trading Activity

POLICY D NOTIFICATION TO THE U.S. FDA FOR BIOLIDICS' COVID-19 RAPID TEST KITS-COMPLETION OF LISTING

[Replacement] Extraordinary/ Special General Meeting: Voluntary

CK LIFE SCIENCES APPOINTED AS A NON-EXCLUSIVE DISTRIBUTOR FOR BIOLIDICS' COVID-19 KITS

[Replacement] Annual General Meeting: Voluntary

ADDITIONAL ARRANGEMENTS FOR AGM AND EGM TO BE HELD ON 30 APRIL 2020

NOTIFICATION TO THE U.S. FDA FOR THE INTENDED DISTRIBUTION OF BIOLIDICS' COVID-19 RAPID TEST KITS

Response to SGX Queries: On Other Announcements

ADDITIONAL ARRANGEMENT FOR AGM AND EGM TO BE HELD ON 30 APRIL 2020

Extraordinary/ Special General Meeting: Voluntary

Annual General Meeting: Voluntary

Annual Reports & Related Documents: Annual Report

PRESS RELEASE: RAPID TEST KIT FOR COVID-19 OBTAINS CE MARKING FOR USE IN THE EUROPEAN UNION

RAPID TEST KIT FOR COVID-19 APPROVED FOR USE BY THE FOOD AND DRUG ADMINISTRATION OF THE PHILIPPINES

Cease to be a Substantial Shareholder - BV Healthcare II Pte. Ltd.

SIGNING OF MANUFACTURER AGREEMENT FOR RAPID TEST KITS TO DETECT NOVEL CORONAVIRUS 2019

PROPOSED ACQUISITION OF THE ENTIRE ISSUED AND PAID-UP ORDINARY SHARES IN THE CAPITAL OF BIOMEDICS

Disclosure of Change in Interest of Substantial Shareholder - SEEDS

Disclosure of Change in Interest of Substantial Shareholder - CBSA

Placements: Completion of Proposed Placement of 17,858,000 New Ordinary Shares in the Capital of Biolidics

Placements: RECEIPT OF LISTING AND QUOTATION NOTICE - PROPOSED PLACEMENT OF 17,858,000 NEW ORDINARY SHARES

Change - Announcement of Appointment: Re-designation of Chief Commercial Officer as Interim Chief Executive Officer

Placements: PROPOSED PLACEMENT OF 17,858,000 NEW ORDINARY SHARES IN THE CAPITAL OF BIOLIDICS LIMITED

PRESS RELEASE: BIOLIDICS TO DEVELOP ITS PROPRIETARY CANCER DIAGNOSTICS SOLUTIONS IN CHINA

Financial Statements and Related Announcement: Full Yearly Results

CHANGE OF COMPANY SECRETARY

PRESS RELEASE: BIOLIDICS AND SYSMEX DEEPENS COLLABORATION WITH DEFINITIVE AGREEMENT

Change of Registered Office

PRESS RELEASE: BIOLIDICS' PARTNER IN CHINA TO LAUNCH COMMERCIAL LDT SERVICE OF PD-L1

PRESS RELEASE: BIOLIDICS' CLEARCELL FX1 SYSTEM OBTAINS APPROVAL IN CHINA

Resignation of Executive Director and Chief Executive Officer

Incorporation of Wholly-Owned Subsidiary In Australia

Press Release:Biolidics To Collaborate With A*Star's Genome Institute Of Singapore

Press Release:Collaboration with Hangzhou Normal University to Undertake Clinical Investigations

Press Release:Biolidics accorded the prestigious "IPOS Award for IP Champions" by WIPO-IPOS

Change - Announcement of Appointment: Appointment of Chief Commercial Officer

Financial Statements and Related Announcement: Half Yearly Results

Incorporation Of Wholly-Owned Subsidiary In The People's Republic Of China

Change - Announcement of Appointment: Appointment of Chief Operating Officer

Request for Lifting of Trading Halt - Sponsor Statement

Request for Lifting of Trading Halt: Request for Lifting of Trading Halt

Clarification of Press Release on 1 July 2019 and Revised Press Release

Request for Trading Halt - Sponsor Statement

Request for Trading Halt: Request for Trading Halt

Press Release: LDT by Biolidics' Partner to be reimbused in China

PRESS RELEASE:BIOLIDICS TO BROADEN PRESENCE IN CHINA CANCER DIAGNOSTICS MARKET WITH NEW PARTNERSHIP

Resignation of Chief Operating Officer

Press Release: Biolidics enters into partnership in China to develop new commercial applications

Annual General Meeting - Presentation Slides

[Replacement] Annual General Meeting: Voluntary

Annual Reports & Related Documents:

Annual General Meeting: Voluntary

Press Release: BIOLIDICS' PARTNER IN CHINA TO OFFER LAB-DEVELOPED TESTS USING BIOLIDICS' PRODUCTS

Financial Statements and Related Announcement: Full Yearly Results

PRESS RELEASE-BIOLIDICS ENTERS INTO A STRATEGIC COLLABORATION WITH SYSMEX CORPORATION

SIGNING OF NON-BINDING TERM SHEET WITH SYSMEX CORPORATION

PROFESSOR XIE TIAN, VOLUNTARILY SUBJECTS HIS REMAINING STAKE IN BIOLIDICS TO A MORATORIUM

Disclosure

Disclosure

Disclosure

Disclosure

Changes in Directo

Changes in Directo

Press Release: Biolidics Limited's IPO attracts strong investor demand

Placement Results

Equity - Listing Confirmation: Admission of 242,500,000 ordinary shares to the Official List of SGX-